Johnson & Johnson submits additional data to FDA on psoriatic arthritis
The submission is supported by results from the Phase 3b APEX study
The submission is supported by results from the Phase 3b APEX study
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Subscribe To Our Newsletter & Stay Updated